ZSCAN4 Inhibition for Cancer Stem Cell Recurrence Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer do not effectively target cancer stem cells, which are responsible for tumorigenicity, aggressive phenotype, and tumor recurrence, and the function of human ZSCAN4 in cancer is not well understood.
Innovation Solution
Inhibit the activity of ZSCAN4 in cancer cells using agents that bind to ZSCAN4 or its interacting proteins, such as RNF20, to disrupt its function and reduce the maintenance of the cancer stem cell phenotype, thereby downregulating CSC markers and inhibiting tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then general tumor mass is reduced, but cancer stem cells are not effectively targeted, leading to tumor recurrence
Solution Approach 1:
The patent applies local quality by developing treatments that specifically target cancer stem cells with distinct molecular characteristics (ZSCAN4 expression, CD44, ALDH1 activity) rather than treating all tumor cells uniformly. This selective targeting addresses the recurrence problem by eliminating the specific subpopulation responsible for tumor regrowth while preserving normal tissue.
Solution Approach 2:
The patent utilizes parameter changes by identifying and targeting specific molecular parameters that distinguish cancer stem cells from differentiated tumor cells, such as ZSCAN4 protein expression levels, CD44 surface markers, and ALDH1 enzymatic activity. These parameter-based distinctions enable selective targeting of the stem cell compartment.
2Reliability
If ZSCAN4 activity is inhibited, then cancer stem cell maintenance is disrupted, but understanding of human ZSCAN4 function in cancer is limited
Solution Approach 1:
The patent applies preliminary action by first comprehensively characterizing ZSCAN4's normal biological functions in embryonic stem cells and early development before applying inhibition strategies. This preliminary understanding of physiological roles guides the development of selective inhibitors that disrupt cancer stem cell maintenance while minimizing off-target effects on normal tissues.
Solution Approach 2:
The patent uses intermediary molecules and pathways to indirectly target ZSCAN4 function. Rather than directly inhibiting ZSCAN4 protein, the approach employs agents that interfere with ZSCAN4's interactions with chromatin, transcription factors, or downstream effectors, thereby suppressing cancer stem cell phenotype while building progressive functional understanding.
Data Source
AI summary
Provided herein are methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of ZSCAN4 in cancer cells in the subject, thereby treating the cancer.